Estetrol (E4) is a fetal estrogen suitable for oncological applications including breast cancer and prostate cancer. The E4 program has successfully reached Phase II. At present clinical studies are ongoing for the treatment of breast cancer in Germany and for prostate cancer in the Netherlands. The ZP program opens a promising way to discover a new immuno-therapy for several cancers, including ovarian cancer, prostate cancer, breast cancer, colorectal cancer and non-small cell lung cancer. The preclinical development of the ZP program is currently ongoing. The program for ovarian cancer has been licensed out to HRA Pharma SA, Paris (France) in 2014. Pantarhei is developing the other applications.
Pantarhei Oncology BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: email@example.com
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Oncology and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.